FR-260010
FR-260010 is a chemical compound that has been studied for its potential pharmacological effects. It is primarily of interest in the field of cardiovascular pharmacology due to its action as a potassium channel opener. This compound has been investigated for its ability to induce vasodilation and its potential therapeutic applications in treating conditions such as hypertension and angina pectoris.
Pharmacodynamics[edit | edit source]
FR-260010 functions by opening ATP-sensitive potassium channels (K_ATP channels) in vascular smooth muscle cells. This action leads to hyperpolarization of the cell membrane, which in turn causes relaxation of the smooth muscle and vasodilation. The opening of these channels reduces intracellular calcium levels, further contributing to muscle relaxation.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of FR-260010 includes its absorption, distribution, metabolism, and excretion. Studies have shown that it is rapidly absorbed when administered orally, with a bioavailability that allows for effective plasma concentrations to be reached. The compound is metabolized primarily in the liver, and its metabolites are excreted via the renal route.
Clinical Applications[edit | edit source]
While FR-260010 has shown promise in preclinical studies, its clinical applications are still under investigation. The primary focus has been on its use as an antihypertensive agent and in the management of ischemic heart conditions. However, further clinical trials are necessary to fully establish its efficacy and safety profile.
Side Effects[edit | edit source]
Potential side effects of FR-260010, as with other potassium channel openers, may include hypotension, dizziness, and headache. These effects are generally related to its vasodilatory action.
Research and Development[edit | edit source]
Research on FR-260010 is ongoing, with studies focusing on its mechanism of action, therapeutic potential, and safety. The compound is part of a broader class of drugs being explored for their cardiovascular benefits.
Also see[edit | edit source]
References[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
